Evaluation of an Advanced, Multimodal Skin Tone Correcting Serum in Participants With Mild-to-Severe Dyschromia and Hyperpigmentation

January 2026 | Volume 25 | Issue 1 | 36 | Copyright © January 2026


Published online December 31, 2025

Zoe Diana Draelos MD FAADa, Diane B. Nelson RN MPHb

aDermatology Consulting Service, PLLC, High Point, NC
bskinbetter science, a Dermatological Beauty Brand of L’Oréal USA Inc., New York, NY

Abstract
Background: A new multimodal skin tone correcting serum formulated with b.r.y.t.e.r. (brown, red, and yellow tones with enhanced resurfacing) technology (EV-I) targets brown, red, and yellow dyschromia and acts through 5 pathways of melanin synthesis to reduce pigmentation, resurface and exfoliate skin, and improve overall skin tone.
Methods: A single-center, open-label, 12-week trial enrolled females with mild-to-severe dyschromia/hyperpigmentation. EV-I was applied twice daily for 12 weeks, with a subset of participants also applying a double-conjugated retinoid/AHA cream (AHARet) nightly. Pigmentation was graded using the Melasma Area and Severity Index (MASI) scale at baseline and at weeks 2, 4, 8, and 12. Skin dullness and texture were assessed using a 6-point grading scale. Erythema and dryness/flaking were assessed using a 4-point grading scale. Participant satisfaction and adverse events (AEs) were collected over 12 weeks.
Results: Sixty-five participants were enrolled (EV-I, n=40; EV-I/AHARet, n=25) with a mean age of 53 years; 78% of participants had Fitzpatrick skin types (FST) I-III, 22% were FST IV-VI. The majority of participants presented with moderate-to-severe dyschromia/hyperpigmentation. Significant percent improvements from baseline were demonstrated based on MASI scores at 12 weeks (EV-I, 42%, EV-I/AHARet, 47% [all, P<.0001]). Significant improvements from baseline were demonstrated in the appearance of skin texture (EV-I, 46%; EV-I/AHARet, 59% [all, P<.0001]) and dullness (EV-I, 47%; EV-I/AHARet, 59% [all, P<.0001]) at 12 weeks. No increases in erythema or dryness/flaking were observed.
Conclusions: A new multimodal skin tone correcting serum demonstrated significant improvements in MASI scores and in the appearance of skin texture and dullness. Significant improvements were also achieved in participants using both the skin tone correcting serum and double-conjugated retinoid/AHA cream. Participants reported high levels of satisfaction over 12 weeks.

 

INTRODUCTION

Melanin provides pigmentation to skin, hair, and eyes and protects epidermal cells by absorbing harmful ultraviolet (UV) rays. Hyperpigmentation results from excess, cumulative melanin triggered by extrinsic aggressors such as UV radiation and pollution, and intrinsic factors including genetics, hormonal fluctuations, and imbalances that induce oxidative stress.1-3

Melanogenesis is a complex biochemical process that involves multiple pathways.4 Among the primary cell signaling pathways that influence skin pigmentation are melanocyte activation, melanosome formation, melanin synthesis, and melanin transfer and removal.4 Melanocyte activation and formation can be triggered by UV exposure, pregnancy, other hormonal fluctuations, inflammation, and aging. Sun exposure causes the body to increase production of melanin to defend against UV rays, increasing skin pigmentation. UV radiation produces free radicals, which, along with UV light, activate biological mechanisms that impact melanocytes.5 In the presence of tyrosinase, a key enzymatic regulator of melanin production,6 the amino acid L-tyrosine is converted to dopaquinone (DOPA), which is then transformed into either eumelanin (black-brown pigmented melanin) or pheomelanin (yellow-red pigmented melanin).4,5 Multiple modalities or agents are often required to manage hyperpigmentation sufficiently, and strategies always include routine, daily use of sunscreen and sun-protective measures. In an effort to address the multiple pathways involved in the development of melanin, recommended regimens often include the adjunctive use of several topical prescription and/or nonprescription products, including hydroquinone (HQ), retinoids, alpha-hydroxy acids (AHAs), and antioxidants.7-13